We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Siemens Healthineers Point of Care Diagnostics

Siemens Healthineers Point-of-Care solutions are designed to provide immediate, convenient, and easy-to-use diagnosti... read more Featured Products: More products

Download Mobile App




New 8-Minute Blood Test to Diagnose or Rule Out Heart Attack Shortens ED Stay

By LabMedica International staff writers
Posted on 03 Sep 2024

Emergency department overcrowding is a significant global issue that leads to increased mortality and morbidity, with chest pain being one of the most common reasons for hospital admissions. More...

Most patients with chest pain, who are hospitalized for extended periods for evaluation of acute coronary syndrome (ACS), turn out to have non-threatening causes like gastro-esophageal reflux. This makes accelerated diagnostic protocols, including high-sensitivity cardiac troponin (hs-cTn) tests, crucial for the quick assessment and early discharge of patients at low risk. Traditional hs-cTn testing requires two blood samples spaced 1-3 hours apart, each taking about 60 minutes to process. In contrast, point-of-care (POC) testing can yield faster results. Now, late-breaking research presented at ESC Congress 2024 highlights a new rapid blood test that could improve the treatment for individuals presenting with chest pain in emergency departments.

This research was part of the WESTCOR-POC clinical trial conducted at Haukeland University Hospital (Bergen, Norway), where the safety and efficacy of a novel 0-hour and 1-hour POC hs-cTn test were compared against the standard laboratory hs-cTn testing. The POC hs-cTn test, Atellica VTLi from Siemens Healthineers (Forchheim, Germany), demonstrated similar accuracy to lab tests. The study involved 1,494 adult patients showing symptoms of ACS, randomized to either the new eight-minute POC test (728 patients) or the conventional lab test (766 patients). Both groups had comparable demographics and patients were admitted or discharged according to the judgment of the attending physician.

Results showed that the median emergency department stay was slightly reduced by POC testing—174 minutes versus 180 minutes for the standard group. For patients seen by a physician within 60 minutes, POC testing cut emergency department time by 15 minutes (147 vs 162 minutes). POC testing significantly benefited patients with non-ST-elevation myocardial infarction (NSTEMI), reducing their emergency department stay by 43 minutes (137 vs 180 minutes), thus allowing quicker admission to the cardiac ward. Discharge rates within 3 and 6 hours and the total length of hospital stay were similar between the two groups, as were safety outcomes. There were comparable rates of death, heart attacks, and acute revascularizations within 30 days post-discharge (11.4% POC vs 9.4% lab), and very few adverse events occurred after discharge in both groups (0.8% POC vs 0.5% lab), confirming that both testing methods are safe and effective.

“This simple test only requiring a drop of blood can be performed within 8 minutes without the need for a laboratory,” said author Viola Thulin from Haukeland University Hospital. “Use of point-of-care testing on arrival at hospital has the potential to speed up earlier diagnosis or rule out heart attack and reduce the amount of time some patients spend in the emergency department.”

Related Links:
Haukeland University Hospital


New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Quality Control Material
Multichem ID-B
New
Automatic Hematology Analyzer
LABAS F9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.